Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00125151
Other study ID # KB2003.01B
Secondary ID
Status Completed
Phase Phase 3
First received July 28, 2005
Last updated May 1, 2009
Start date February 2006
Est. completion date April 2007

Study information

Verified date May 2009
Source Sanquin
Contact n/a
Is FDA regulated No
Health authority Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)
Study type Interventional

Clinical Trial Summary

A multicentre study to investigate the pharmacokinetics, clinical efficacy and safety of nanofiltered Cetor® (called C1-esteraseremmer-N during the development phase) for the treatment of hereditary angioedema (HAE) will be performed. This study (KB2003.01) consists of three parts: Part A - pharmacokinetics (phase II); Part B - treatment of attacks of angioedema (phase III); and Part C - prophylactic use of C1 inhibitor (phase III). Parts B + C will provide data on the efficacy of C1-esteraseremmer-N.

The changes within the manufacturing process of C1-esteraseremmer-N, compared to Cetor® nanofiltration and omission of hepatitis B immunoglobulin, most likely will not affect tolerability. The nanofiltration will provide more safety regarding viruses.

In Part B of the study, 15 attacks of hereditary angioedema will be treated with open-label C1-esteraseremmer-N. Attack severity and duration will be monitored by the subjective experience of the patient himself (which has been shown to be the most sensitive way of monitoring attack severity) and compared with historical (and literature) data. If possible, some attacks of acquired angioedema will also be included.


Description:

A multicentre study to investigate the pharmacokinetics, clinical efficacy and safety of nanofiltered CetorĀ® (called C1-esteraseremmer-N during the development phase) for the treatment of hereditary angioedema (HAE) will be performed. This study (KB2003.01) consists of three parts: Part A - pharmacokinetics (phase II); Part B - treatment of attacks of angioedema (phase III); and Part C - prophylactic use of C1 inhibitor (phase III). Parts B + C will provide data on the efficacy of C1-esteraseremmer-N.

The changes within the manufacturing process of C1-esteraseremmer-N, compared to CetorĀ® nanofiltration and omission of hepatitis B immunoglobulin, most likely will not affect tolerability. The nanofiltration will provide more safety regarding viruses.

In Part B of the study, 15 attacks of hereditary angioedema will be treated with open-label C1-esteraseremmer-N. Attack severity and duration will be monitored by the subjective experience of the patient himself (which has been shown to be the most sensitive way of monitoring attack severity) and compared with historical (and literature) data. If possible, some attacks of acquired angioedema will also be included.


Recruitment information / eligibility

Status Completed
Enrollment 15
Est. completion date April 2007
Est. primary completion date
Accepts healthy volunteers No
Gender Both
Age group 16 Years and older
Eligibility Inclusion Criteria:

Inclusion criteria for HAE type I and type II patients:

- Established diagnosis of hereditary angioedema (type I or II): markedly decreased C1 inhibitor activity; decreased (type I), normal or elevated (type II) level of C1 inhibitor antigen; decreased level of C4.

- Age = 16 years

- Evidence of a peripheral, abdominal, facial, laryngeal or genitourinary attack of angioedema of moderate to severe intensity, starting less then 5 hours before infusion. An attack is defined as moderate if it affects the normal daily activities of the patient in any way. Severe attacks are defined by the inability to perform normal daily activities.

- Signed informed consent by patient and patient's legal representative if under 18 years old

Inclusion criteria for acquired angioedema patients:

- Established diagnosis of acquired angioedema: recurrent attacks of angioedema without urticaria; no family history; decreased functional C1 inhibitor; decreased level of C4.

- Autoantibodies to C1 inhibitor or decreased C1q or onset after the third decade of life.

- Age = 16 years

- Evidence of a peripheral, abdominal, facial, laryngeal or genitourinary attack of angioedema of moderate to severe intensity, starting less then 5 hours before infusion. An attack is defined as moderate if it affects the normal daily activities of the patient in any way. Severe attacks are defined by the inability to perform normal daily activities.

- Currently treated with C1 inhibitor concentrate to reverse angioedema.

- Signed informed consent by patient and patient's legal representative if under 18 years old

Exclusion Criteria:

Exclusion criteria for HAE type I and type II patients:

- Presence of clinically-relevant anti-C1 inhibitor auto-antibodies

- Participation in another pharmaceutical clinical study, which can interfere with this study, in the last 3 months prior to the study, other than Part A of this protocol.

- Addiction to narcotic/pain medication in case of an abdominal attack

- B-cell malignancy

- Use of narcotic medication within 3 days prior to attack.

- Use of heparin within the last two days prior to the study

- Pregnancy or lactation

- History of allergic reactions to C1 inhibitor concentrate or other blood products

Exclusion criteria for acquired angioedema patients:

- Participation in another pharmaceutical clinical study, which can interfere with this study, in the last 3 months prior to the study

- Addiction to narcotic/pain medication in case of an abdominal attack

- Use of narcotic medication within 3 days prior to attack.

- Use of heparin within the last two days prior to the study

- Pregnancy or lactation.

- History of allergic reactions to C1 inhibitor concentrate or other blood products

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
C1 inhibitor concentrate (C1-esteraseremmer-N)


Locations

Country Name City State
Netherlands Academic Medical Centre Amsterdam
Netherlands Academic hospital Groningen Groningen
Netherlands Erasmus Medical Centre Rotterdam

Sponsors (1)

Lead Sponsor Collaborator
Sanquin

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Primary The primary objective in this clinical study, in which patients use C1-esteraseremmer-N to treat an attack of angioedema, is to investigate the efficacy and the time-to-effect of C1-esteraseremmer-N.
Secondary Secondary objectives are the safety of C1-esteraseremmer-N and the ability of C1-esteraseremmer-N to increase the C1 inhibitor level and activity.
See also
  Status Clinical Trial Phase
Not yet recruiting NCT00163839 - The Efficacy of a Pseudoallergen-Free Diet in the Treatment of Chronic Idiopathic Urticaria and/or Angioedema N/A
Recruiting NCT04597944 - Lanadelumab in Bradykinin Angioedema
Recruiting NCT03845946 - CLOUD-R HAE REGISTRY
Completed NCT00876369 - Vitamin D Levels in Subjects With Chronic Urticaria and Angioedema
Completed NCT02833675 - Determination of Specific Biomarkers of Angioneurotic Crisis N/A
Completed NCT06096077 - Evaluation of Tranexamic Acid for Angiotensin-converting Enzyme Inhibitor-induced Angioedema in the Emergency Department
Completed NCT00125541 - C1-Esteraseremmer-N for the Treatment of Hereditary (and Acquired) Angioedema Phase 2/Phase 3
Completed NCT01371877 - The Role of Vitamin D in Chronic Urticaria and Angioedema Treatment N/A
Completed NCT04206605 - A Study of Lanadelumab in Teenagers and Adults to Prevent Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH) Phase 3
Unknown status NCT01036659 - Evaluation of Ecallantide for the Acute Treatment of Angiotensin Converting Enzyme Inhibitor Induced Angioedema Phase 2
Recruiting NCT05578417 - A Study to Review the Treatment and Outcomes of Teenagers and Adults With Non-histaminergic Angioedema With Normal C1 Inhibitor in Canada
Recruiting NCT05936567 - Study Evaluating the Efficacy and Safety of Povorcitinib in Adults With Chronic Spontaneous Urticaria Phase 2
Recruiting NCT04334031 - Deployment o the Multidisciplinary Prospective Cohort Imminent N/A
Completed NCT03240991 - Study of Clinical, Biological Characteristics and Quality of Life of Patients With Hereditary or Acquired Non Drug-induced Bradykinin-mediated Angioedema, Monitored in Besançon's Partner Site Reference Center for Studies of Kinin-mediated Angioedema (CREAK)
Completed NCT01723072 - Impact of Omalizumab on Quality of Life Measures and Angioedema Occurrence in Patients With CSU Refractory to Therapy Phase 3
Completed NCT00385372 - Significance of an Elimination and Provocation Diet in Patients With Chronic Urticaria N/A
Completed NCT00004694 - Study of Heparin Prophylaxis of Hereditary Angioedema Exacerbations N/A
Not yet recruiting NCT06210698 - Angioedema Biomarker Research Study
Terminated NCT04128371 - Mepolizumab in Episodic Angioedema With Eosinophilia Phase 2
Completed NCT04444895 - A Study of Long-Term Safety and Efficacy of Lanadelumab for Prevention of Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor Phase 3